"Topical Gel Will Undergo Further Studies Against Foot Infections"
The drug candidate SB208 (Novan, Inc.) has been found to be safe and efficacious for treating tinea pedis, according to the results of a phase 2 trial. It is a broad-spectrum antifungal topical based on a nitric oxide platform. "This tells us that this is a potent drug, even four weeks after stopping treatment," said Leon Kircik, MD, a clinical professor of dermatology at the Icahn School of Medicine at Mount Sinai. Dr. Kircik anticipates that the antifungal drug will become commercially available in the next couple of years.
- Leon Kircik, MD, Clinical Associate Professor, Dermatology, Icahn School of Medicine at Mount Sinai